An Integrated Microfluidics Approach for Personalized Cancer Drug Sensitivity and Resistance Assay

Area of Science:

• Oncology
• Biomedical Engineering
• Drug Discovery

Background:

• Cancer is a leading global cause of death, necessitating effective and personalized treatments.
• Current cell-based drug testing is limited by difficulties in expanding patient tumor samples in culture.
• Personalized medicine seeks to tailor treatments to individual patients, but faces challenges in drug response prediction.

Purpose of the Study:

• To develop and validate a microfluidic device for high-throughput drug chemosensitivity testing.
• To investigate the differential drug response of cancer cells based on their morphology within the device.
• To demonstrate the potential of microfluidic drug microarrays for personalized cancer therapy.

Main Methods:

• A novel microfluidic device integrating a drug microarray and cell microscopy was designed.
• The device enabled 512 simultaneous experiments to test drug sensitivity and resistance.
• MCF7 and 293T cells were exposed to docetaxel at various concentrations, and cell mortality was assessed.

Main Results:

• Cancer cells formed distinct cluster morphologies within the microfluidic device, unlike conventional cultures.
• Cells within these clusters exhibited lower sensitivity to docetaxel compared to dispersed cells.
• The study confirmed heterogeneous drug responses within cancer cell populations.

Conclusions:

• Microfluidic devices can reveal complex cellular behaviors like cluster formation, influencing drug response.
• Drug microarrays on microfluidic platforms show promise for personalized cancer treatment strategies.
• This technology may lead to improved patient outcomes through tailored therapeutic interventions.